{"id":"W2040200721","doi":"10.3851/imp1959","title":"Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Janssen Canada","keywords":"Rilpivirine; Efavirenz; Pharmacokinetics; Medicine; Pharmacology; Ex vivo; Internal medicine; In vivo; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004105596,0.0002294393,0.0003390207,0.0001863903,0.0001675923,0.0002913042,0.0001118207,0.0003298256,0.0008504766],"category_scores_gemma":[0.00102549,0.0001417187,0.0001556092,0.0001552307,0.0001338224,0.0001752436,0.00008142718,0.0003466384,0.0002792913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000207195,"about_ca_system_score_gemma":0.0001538365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008691687,"about_ca_topic_score_gemma":0.0005324604,"domain_scores_codex":[0.9997608,0.00006279175,0.00001388194,0.00008404157,0.0000569402,0.00002158211],"domain_scores_gemma":[0.9996684,0.0001007905,0.0001017536,0.0000343633,0.00004020692,0.00005454751],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.03934383,0.002191622,0.6916265,0.0002047624,0.0006743413,0.0009141091,0.0006959656,0.002559319,0.1699529,0.0001560594,0.001061127,0.09061944],"study_design_scores_gemma":[0.0003135001,0.01444229,0.9682188,0.000008379269,0.0001620294,0.002096656,0.00009466759,0.002587846,0.01091869,0.00008452438,0.001047409,0.00002515197],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998604,0.0004215593,0.0002952052,0.000009041068,0.000003662183,0.00002401401,0.0002549312,0.00002128264,0.0003662869],"genre_scores_gemma":[0.9989365,0.00009901432,0.0003472554,0.00002211901,0.000006432224,0.00002037658,0.0002897774,0.000003392639,0.0002750471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008691687,"threshold_uncertainty_score":0.002845109,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05700164969134133,"score_gpt":0.3226173704849523,"score_spread":0.265615720793611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}